Edition:
India

Infinity Pharmaceuticals Inc (INFI.OQ)

INFI.OQ on NASDAQ Stock Exchange Global Select Market

1.97USD
11:47pm IST
Change (% chg)

$-0.08 (-3.90%)
Prev Close
$2.05
Open
$2.05
Day's High
$2.05
Day's Low
$1.96
Volume
60,418
Avg. Vol
413,191
52-wk High
$3.84
52-wk Low
$0.93

Chart for

About

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145,... (more)

Overall

Beta: 2.69
Market Cap(Mil.): $80.60
Shares Outstanding(Mil.): 50.69
Dividend: --
Yield (%): --

Financials

BRIEF-Infinity Expects Net Loss For 2018 To Range From $40 Mln To $50 Mln​

* INFINITY PHARMACEUTICALS INC - ‍INFINITY EXPECTS NET LOSS FOR 2018 TO RANGE FROM $40 MILLION TO $50 MILLION​

08 Jan 2018

BRIEF-Infinity Q3 loss per share $0.14

* Infinity provides company update and reports third quarter 2017 financial results

07 Nov 2017

BRIEF-Verastem makes milestone payment to Infinity Pharmaceuticals

* Verastem pays milestone payment to Infinity Pharmaceuticals

17 Oct 2017

BRIEF-Infinity Pharmaceuticals and Bristol-Myers Squibb expand clinical collaboration

* Infinity Pharmaceuticals and Bristol-Myers Squibb expand clinical collaboration evaluating ipi-549 in combination with Opdivo (nivolumab)

25 Sep 2017

BRIEF-Infinity Q2 loss per share $0.34

* Infinity provides company update and reports second quarter 2017 financial results

04 Aug 2017

BRIEF-Infinity amends PI3K-Delta,Gamma Agreement with Takeda Oncology

* Infinity amends PI3K-Delta,Gamma Agreement with Takeda Oncology

27 Jul 2017

Competitors

Earnings vs. Estimates